| Indication | Multiple Sclerosis |
| Status | – US Launched on February 13, 2023 by Cycle Pharma. – Exclusive License Agreement with Cycle Pharmaceuticals Ltd. for Commercialization of Tascenso ODT in the USA on March 4th, 2022. – Final approval for 0.25mg & 0.5mg. |
| Product Advantages | Orally disintegrating tablet format is generally known to be of particular relevance to patients with swallowing difficulties. Handa ODT product is relevant to patients who have some level of dysphagia, patients who need to switch therapies due to efficacy or tolerability issues with current therapy, and patients who prefer ODT administration. |
| Market Size | According to the data in 2021 annual report of the brand company, the total sales of the brand drug were US$2.787 billion (US$1.427 billion in the U.S. and US$1.36 billion rest of world). |
?
R&D
Tascenso ODT
